Ken Griffin Uro Gen Pharma Ltd. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$12.7 - $17.92 $193,040 - $272,384	-15,200 Reduced 60.8%	9,800 $124,000
Q2 2024 Aug 14, 2024	BUY	$12.72 - $19.2 $33,072 - $49,920	2,600 Added 11.61%	25,000 $419,000
Q1 2024 May 15, 2024	BUY	$13.81 - $19.33 $19,334 - $27,061	1,400 Added 6.67%	22,400 $336,000
Q4 2023 Feb 14, 2024	SELL	$10.87 - $15.93 $70,655 - $103,545	-6,500 Reduced 23.64%	21,000 $315,000
Q3 2023 Nov 14, 2023	BUY	$8.84 - $22.64 $153,816 - $393,936	17,400 Added 172.28%	27,500 $385,000
Q2 2023 Aug 14, 2023	SELL	$8.75 - $14.29 $399,875 - $653,053	-45,700 Reduced 81.9%	10,100 $104,000
Q1 2023 May 15, 2023	SELL	$7.99 - $11.02 $311,610 - $429,780	-39,000 Reduced 41.14%	55,800 $515,000
Q4 2022 Feb 14, 2023	BUY	$7.55 - $11.96 $565,495 - $895,804	74,900 Added 376.38%	94,800 $840,000
Q3 2022 Nov 14, 2022	BUY	$7.21 - $9.41 $143,479 - $187,259	19,900 New	19,900 $166,000

130

35.9M

22K

93.8K

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $254M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.